SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary

March 27, 2025

NASDAQ US Health Care Health Care Equipment and Supplies earnings

Earnings Call Speaker Segments

Jackie Cossmon

executive
#1

Calvin, thanks. Good afternoon, and I appreciate everyone being on the call for SeaStar Medical's fiscal 2024 year-end results discussion. This is Jackie Cossmon, speaking on behalf of Wheelhouse Life Science Advisors. With me from SeaStar Medical this afternoon are Eric Schlorff, our Chief Executive Officer; David Green, our Chief Financial Officer; Dr. Kevin Chung, our Chief Medical Officer; and Tim Varacek, Senior Vice President of Commercial and Business Operations. A reminder for those listening: remarks delivered by management on this call will contain forward-looking statements as defined under the federal securities laws. Such forward-looking statements carry risks and uncertainties that might lead actual outcomes to differ materially from any projected outcomes. To see a list and descriptions of those risks and uncertainties, please consult SeaStar Medical's filings with the Securities and Exchange Commission at SEC.gov. Also, what is said on this conference call is accurate only as of the moment of the live broadcast, March 27, 2025. Aside from situations where the law requires it, SeaStar Medical assumes no duty to revise or update any statements so they reflect subsequent events or circumstances. I'd now like to hand things over to Eric. Eric?

Eric Schlorff

executive
#2

Okay, thanks Jackie, and I appreciate everyone being here today. We're eager to tell you about what we accomplished during the last year and, even more significant, what lies ahead and how strongly we feel about the work being done at SeaStar Medical. Since QUELIMMUNE came to market — Tim will cover that in a moment — we've seen genuinely remarkable results for patients, with our SCD therapy having preserved lives. Investigators at the University of Michigan recently submitted one such case for publication: that patient faced a 95% predicted mortality, yet following SCD therapy now has normal kidney function, has gone back on chemotherapy, and is home. We've likewise seen halting of what was nearly guaranteed severe organ harm, plus kids leaving the ICU without ever needing renal replacement therapy for the rest of their lives. To us, these extraordinary clinical cases are powerful evidence of what our SCD therapy could offer the roughly 1 million patients who annually confront the effects of devastating hyperinflammation capable of injuring vital organs and ending lives. As we see it, treating additional serious inflammatory conditions over the longer term — cardiorenal syndrome, hepatorenal syndrome, and chronic dialysis among them — stretches our potential far past the initial market we've pinpointed for SCD therapy. Put simply, our opportunities have us energized, and we view 2025 as a period of expansion and momentum, as additional top-tier pediatric medical centers take up QUELIMMUNE and as our clinical development work with places such as Stanford, Cleveland Clinic, and Mayo Clinic progresses toward the NEUTRALIZE-AKI Adult Pivotal Study, which would deliver our second therapeutic product into a market 50x bigger than the significant but smaller one for pediatric AKI patients. Fueling the strong momentum we carry into 2025 are the major things we got done in 2024. Besides securing the first approval of any product, for QUELIMMUNE, we moved the NEUTRALIZE-AKI clinical development program forward and lowered trial costs by gaining CMS coverage that pays for specific expenses medical centers incur when treating Medicare or Medicaid patients taking part in the trial. We additionally earned our fourth Breakthrough Device designation, this one for chronic dialysis, and deepened the medical community's grasp of our SCD therapy via manuscripts in major journals and talks at medical conferences. On top of that, we fortified protection of our first-in-class proprietary technology by winning key patents in the United States and Canada. We further named David Green, a veteran of the healthcare industry, to serve as our Chief Financial Officer in January of 2024. Throughout this transition into a commercial stage company, Dave has worked tirelessly on managing our capital structure, bringing in more capital, and reinforcing our control environment. Success has marked the start of 2025; within only three months, we brought on two new customers — commercial customers — following our 2024 shift in the sales and distribution model. During the call, we announced the activation of two more sites for our NEUTRALIZE-AKI Pivotal Clinical Study, and the FDA gave the green light to a feasibility study for our SCD therapy, looking at it as a treatment for cardiorenal syndrome functioning as a bridge to left ventricular assist device implantation. Only last week, the National Kidney Foundation, which is a well-known advocacy organization focused on kidney disease, revealed that SeaStar Medical would receive its 2025 Corporate Innovator Award. That award exists to honor industry leaders who push nephrology forward either by tackling an unmet clinical need or by making existing practice, therapeutic approaches, or technology better. This year, we received the honor because of the major contribution we've made toward bettering the lives of pediatric patients with AKI, which stems from the approval and launch of our QUELIMMUNE therapy. Those who won before us include Merck, Johnson & Johnson, and UnitedHealthcare. For our team at SeaStar Medical, this recognition means a great deal, and we remain committed to enhancing clinical outcomes. Now, prior to handing things over to Tim on the call, I want to discuss what we anticipate for QUELIMMUNE as a commercial product. We're currently in the launch phase of commercializing our first product into a small market that we estimate at roughly 4,000 pediatric patients each year in the United States. Like any launch, some unpredictability exists, and how long it takes accounts to convert can fluctuate considerably. With QUELIMMUNE, this dynamic gets even more complicated, particularly since our adoption process involves collaborating with Investigational Review Boards, or IRBs, to put the patient registry in place; that forms part of what we committed to the FDA under the Humanitarian Device Exemption approval. As I mentioned before, the feedback we've gotten so far from our first commercial customers has us thrilled, and we currently have a growing pipeline of customers moving through the adoption process. Our 2024 sales have mirrored the timelines needed to onboard customers and get them comfortable with folding QUELIMMUNE into their workflow protocols. Once this process turns into something more routine for them, we anticipate customers will broaden their use of QUELIMMUNE to additional patients who satisfy the criteria for using the therapy; put another way, our sales will be lumpy as we navigate the launch of QUELIMMUNE and grow its use at new sites. During this early stretch, the metric that matters more to watch will be how many institutions are going through the adoption process, since that will eventually translate into product sales and rising revenue. We plan to give updates on how many customers are working through the IRB adoption process, offering a more meaningful metric on the launch; we aren't issuing guidance because of the uncertainties that come with launching a product, but we will say that our progress pleases us and we believe we're on track to hit our internal revenue targets for 2025. With that, I'd like to hand the call over to Tim.

Tim Varacek

executive
#3

Thank you, Eric, and I appreciate all of you being with us on this SeaStar Medical call. Let me begin by emphasizing a few things regarding our QUELIMMUNE therapy. To begin with, this treatment genuinely offers fresh optimism for seriously ill kids, their loved ones, and the clinicians who care for them. The children receiving QUELIMMUNE face an extremely grim outlook, with a death rate exceeding 50% when they get the best currently available care, which consists of continuous renal replacement therapy — CRRT for short — along with antibiotics. Before QUELIMMUNE became available, nothing had been approved — neither a therapy nor a drug — to halt the cytokine storm that creates a substantial danger of multiple organ failure and death among these young patients. The clinical findings for QUELIMMUNE that the FDA examined when deciding to clear the product via Humanitarian Device Exemption, or HDE, showed that nearly 8 out of 10 pediatric patients suffering from acute kidney injury together with sepsis lived when QUELIMMUNE was part of their treatment, compared with just 5 out of 10 patients receiving the standard of care. That works out to an observed survival rate 60% higher. These results have generated tremendous enthusiasm among the most prestigious children's medical centers, spanning regional and community pediatric hospitals. Pediatric medical centers genuinely want to introduce QUELIMMUNE at their institutions, and I'm happy to share that the count of pediatric hospitals moving through the adoption process doubled between the third quarter and the fourth quarter of 2024. That figure grew even more during the first quarter of this year, as we keep adding new pediatric hospitals to the queue of those seeking to adopt QUELIMMUNE. As I noted, we presently have five pediatric hospitals that are operational, have made their purchases, and are using QUELIMMUNE therapy. The adoption process for any new device at these medical centers can take a long time, and it includes standard steps like identifying a product champion, completing a site's value assessment, and being established as a qualified vendor. With QUELIMMUNE specifically, the FDA's post-approval registry mandate introduces one more step into the process, and that generally requires additional time. Every hospital system operates somewhat differently within the mandatory regulatory structure, and we adapt our support to help them finish the process as fast and smoothly as we can. In the end, everything comes down to time to activation, which may range anywhere from several months up to 8 to 10 months. We keep refining how we support pediatric hospitals as we come to understand their particular processes and identify efficiencies that we can frequently apply going forward. Let me be clear — I've gone into extra detail about the activation process because I want to stress the considerable gap we bridge between the wish to adopt our QUELIMMUNE therapy and the drawn-out process of pediatric hospital activation, and to underscore the deep dedication to championing this effort that pediatric nephrology and ICU teams are showing as we work through adoption alongside them. To put it another way, we don't see adoption at these pediatric hospitals as a question of whether it will happen, but rather of timing — and based on our internal tracking so far, 7 out of every 10 pediatric hospitals that we contact to assess interest end up deciding to adopt QUELIMMUNE therapy. I'm delighted to report that the pediatric hospitals currently activated are seeing solid outcomes, and QUELIMMUNE sales rose nicely in the first quarter of 2025 relative to the fourth quarter of 2024. As Eric noted, sales will remain lumpy until additional pediatric hospitals come online and until we develop an understanding of how patient presentation flows within those hospitals; with that picture of our QUELIMMUNE launch work in place, I'll turn now to the commercial opportunity for the SCD therapy platform. As was said, the pediatric AKI market is a small one, yet the unmet medical need for treatment there is extremely high. Securing approval of QUELIMMUNE for this patient population represented the fulfillment of a hugely important chance to bring a therapy to children in desperate need of one — a therapy that could genuinely save their lives or lessen or remove the need for long-term renal replacement therapy. To frame the market opportunity from the perspective of SeaStar Medical's first product launch, our estimate, grounded in our internal assumptions, puts the total addressable market at roughly $100 million. Naturally, we won't win the entire market, but because the clinical need is so serious and no treatments exist today, we expect that in time we will reach a meaningful share of this patient population with QUELIMMUNE therapy, producing steady initial revenue for SeaStar Medical. The indications we pursue later address far bigger markets, and we are following a solid development path toward further approvals and establishing a presence in those markets. Our technology can scale across multiple indications, and our Breakthrough Device designations ought to make the SCD therapy's FDA review a tight process. The adult AKI indication under study in our pivotal trial, NEUTRALIZE-AKI, offers an opportunity roughly 50x the size of the pediatric population — about 200,000 patients each year who confront organ failure and possible loss of life, with no FDA-approved treatment options apart from the current standard of care consisting of CRRT and antibiotics. Assuming positive clinical trial results and FDA approval, our anticipated launch timeline in adult AKI is the second half of 2026. We expect the time to adoption to be more favorable than in pediatric AKI, since we should be able to draw on customer learnings and experience with QUELIMMUNE in hospital systems where a commercial presence already exists, along with the fact that no other therapies address this condition. At our current projected revenue per patient, that would represent a total market opportunity of $4.5 billion. Even under modest market penetration projections, the revenue upside for SeaStar Medical would be significant. From where we sit, the adult AKI indication represents merely the first of many possible indications down the road; we figure the overall market comes to roughly 1 million patients who right now lack any approved treatments for things like chronic dialysis, cardiorenal syndrome, hepatorenal syndrome, acute respiratory distress syndrome, plus additional indications our SCD therapy might address. That is exactly what has us so enthusiastic here at SeaStar Medical, and at this point I'll hand things over to Kevin Chung, our Chief Medical Officer. Kevin.

Kevin Chung

executive
#4

Thank you, Tim, and I appreciate all of you listening joining us. It's a pleasure to share that enrollment in our NEUTRALIZE-AKI pivotal trial is moving along at a consistent rate, with 94 subjects signed up out of the 200 we expect. As a lot of you are aware, NEUTRALIZE-AKI is a randomized, controlled pivotal study built to establish if as many as 10 sequential 24-hour rounds of the SCD therapy can boost 90-day survival or recovery from kidney failure among patients suffering AKI who need CRRT, versus CRRT by itself. Our intention is to enroll roughly 200 patients in an intensive care unit setting for this trial. The primary endpoint combines mortality or dialysis dependency at 90 days; our plan is to run an interim analysis after the 90-day primary endpoint has been reached in the first 100 subjects enrolled. We will analyze pooled data and bring it before our Data Safety Monitoring Board, known as the DSMB. At that point, judging by how outcomes differ between treated subjects and controls, the DSMB will give SeaStar Medical and the NEUTRALIZE-AKI investigators a recommendation on how the trial should proceed. Although we cannot know for sure what the independent DSMB will recommend, we built the interim analysis to make certain the study was properly powered, and assuming that's the case, the DSMB's conclusion would be to keep going as planned toward our target of 200. We're confident we'll hit 100 patients at some point in April. With the new sites we've recently activated, we expect enrollment to continue steadily, perhaps even speed up, for the remainder of the year. Lately we've dealt with some difficulties stemming from a nationwide citrate shortage affecting our CRRT circuits together with the SCD; even so, we still enrolled 24 new subjects within only the last three months. Fortunately, that shortage has been resolved. We feel tremendous gratitude toward our outstanding investigators, who leaped through numerous hurdles to get subjects enrolled. Since the start of this year, we've also brought on two additional sites, with the University of Texas Southwestern in Dallas being the most recent addition. As Eric noted, a number of distinguished medical institutions, among them Stanford, Cleveland Clinic, and Mayo Clinic, are now enrolling patients in the NEUTRALIZE-AKI study. I'm calling attention to these sites because they, along with other leading sites, are the ones we expect to serve as our early clinical champions when the moment arrives to bring this therapy to the adult ICU market. Rest assured they will carry definitive outcomes data from our pivotal trial. Beyond that, we know plenty of these champions will relate their own firsthand experience to the international critical care and nephrology communities, aiming ultimately to get our therapy written into clinical practice guidelines. A successful NEUTRALIZE-AKI trial will assist in raising the current standard of care for everyone battling life-threatening AKI. We consider ourselves very lucky to have the right investigators at the right sites taking part in our trial. As soon as the trial wraps up and we reach a full 100% data lock, our plan is to move quickly on analyzing and reporting the results to the international medical community. If our primary endpoint is met, our intention is to finish the PMA filing and send it in to the FDA. We hold the Breakthrough Device designation for adult AKI, and that ought to make communication with the FDA faster while they review and decide on approval, so we're hopeful this product can reach patients at some point during the second half of 2026. Now, when we look ahead, our stepwise aim is to drive broad clinical adoption of the SCD therapy — starting by treating as many as possible of the roughly 200,000 patients in the U.S. with AKI, and then, at the right moment, going outside U.S. borders to reach as many as possible of the millions of patients around the world who might benefit from our SCD therapy for this indication. As a company, our strategic objective is to expand the addressable market quickly so we can target other critical unmet medical needs. I want to stress that NEUTRALIZE-AKI is truly three trials rolled into one. We plan to analyze and report how the SCD performs in the cohort of patients with sepsis and ARDS as well. Given how the SCD works, we have solid grounds to believe we can demonstrate benefit in these two subpopulations. Past this indication, we've been granted Breakthrough Device designation for three additional ones, covering treatment of patients with cardiorenal syndrome, patients with hepatorenal syndrome, and patients with end-stage renal disease. Because our therapy is organ and disease-agnostic in nature, there are several more indications still to come. In our view, AKI is only the start. On top of that, we announced last year that the NIH gave a $3.6 million grant for a clinical trial evaluating our SCD therapy in patients with cardiorenal syndrome who are awaiting LVAD implantation. In January, the FDA approved a feasibility study for this indication. The trial will be led by the SCD therapy's inventor, Dr. David Humes from the University of Michigan, who is also one of our key scientific advisors. NEUTRALIZE-CRS is expected to enroll 20 patients across up to five clinical sites. Results from this pilot study will help guide our next steps for this indication. Our medical affairs and research team is collaborating closely with Tim and his commercial team to determine the most appropriate next best disease state to tackle with our disease and organ-agnostic therapy; with that, as a summary of our clinical development efforts and goals, I'll hand the call over to our CFO, David Green.

David Green

executive
#5

Thanks, Kevin, and I appreciate everyone being here today. I'll begin with a handful of remarks regarding our fiscal year that closed on December 31, 2024, then wrap up with certain expectations we hold for 2025. To begin with a bit of housekeeping: our Form 10-K is going to be submitted to the SEC within the coming 24 hours. It's available at SeaStarMedical.com or through SEC.gov. As my colleagues have already told you, 2024 proved to be a year of transformation for SeaStar Medical. We achieved significant progress in fortifying our financial standing, securing FDA clearance to market and introduce QUELIMMUNE, which is our inaugural commercial offering for pediatric use, and advancing our NEUTRALIZE-AKI pivotal study for adults suffering from AKI. Looking at the financial side, I'm quite happy with how we performed in 2024; we meaningfully bolstered the balance sheet by bringing in fresh capital while lowering debt along with other liabilities. We brought in roughly $25 million, and we exercised considerable caution regarding how that new capital was deployed. Operations received $16 million in funding, with the bulk directed toward our adult clinical trials and commercializing QUELIMMUNE for pediatrics. Roughly $6 million of debt was retired. Accounts payable came down by $1.3 million, and we finished the year holding $1.8 million in cash. On top of that, as we shared last month, we brought in an additional $6 million during February of this year. Beyond reinforcing the balance sheet, we remediated and resolved previously existing material weaknesses and put far stronger controls in place governing financial reporting. With that difficult work now finished, the company is positioned to expand upon the first two quarters of commercial revenue for QUELIMMUNE and to finish the adult AKI pivotal trial. Turning to the commercial side, following FDA clearance for our pediatric product QUELIMMUNE in Q1 2024 and its Q3 2024 launch, we executed a major strategic shift away from a distribution network model toward selling directly. This shift lets us completely oversee the sales and distribution cycle while steering clear of expensive distribution fees. It also enables us to make better use of our product knowledge and our close ties with ICU and nephrology clinicians at the hospitals we target. That decision has been delivering results. As Tim mentioned previously, an extremely high proportion of hospitals we contact to assess interest end up committing to adopt QUELIMMUNE therapy for their pediatric patients. Ultimately this will produce an expanding customer base and iron out some of the early unevenness in order patterns that typically occurs during an initial launch phase; now that the sales model realignment is finished, we're well positioned to expand upon the first two quarters of commercial revenue for QUELIMMUNE and to finish the adult AKI pivotal trial. Now, a few top-line remarks regarding our income statement. With QUELIMMUNE launching in the third quarter, we recorded our first product revenue during 2024, posting net revenue of $134,000; that modest figure mirrors the timing around customer adoption, just as Tim explained. Although we think sales will be uneven during the early stages of the launch, we do expect a general pattern of revenue growth as the total count of customers buying QUELIMMUNE rises. Actually, I'm happy to say that thanks to the ongoing addition of purchasing customers, we've observed a pleasant increase in sales so far during the first quarter. All in all, we feel quite positive about new hospitals becoming customers as we allow more children to gain from our life-saving therapy. Turning to our Cost of Goods Sold, the present financial statements show no GAAP Cost of Goods Sold stemming from sales of QUELIMMUNE. Under GAAP accounting, inventory must be expensed as research and development costs for that inventory, which had been built before we received FDA approval to sell QUELIMMUNE. Once we acquire, build, and sell new inventory as a commercial company, we will record those expenses as Cost of Goods Sold in line with GAAP accounting. We expect these costs to reach the P&L later this year. Our operating expenses for 2024 rose by roughly $3.6 million relative to 2023, mainly because of higher spending on our commercial launch and rising enrollment in the NEUTRALIZE-AKI trial. Our net loss for the year drops to $24.8 million against a loss of $26.2 million in 2023, and approximately $6.9 million of the 2024 loss came from non-cash items. Going forward, we intend to concentrate our resources on our top three objectives. First, commercial sales of QUELIMMUNE. Second, finishing our NEUTRALIZE-AKI pivotal trial for adults. Third, getting ready to file a PMA once the adult pivotal trial is complete; we are extremely enthusiastic about serving the adult AKI population, which is estimated to be about 50x bigger than the pediatric population. As we advance our strategic objectives, we expect the momentum to keep building as we bring our life-saving SCD therapy to additional patients and clinicians and as more investors take note of the substantial market opportunity taking shape for our products; with that, I'll hand the call back to Eric.

Eric Schlorff

executive
#6

Okay, thank you, David. What we aimed to accomplish today with this first-ever quarterly earnings call was to give everyone an overview of what we've already achieved during 2024 and the beginning of 2025, and to lay out clearly the reasons we see big future potential at SeaStar Medical; since we now have a product being sold commercially and a short-term chance to claim a meaningful share of a vast market tied to treating adults who have AKI and are on CRRT, we see SeaStar Medical as a strongly differentiated business whose assets carry less risk and which is ready to grow. Past those indications, we think three main elements speed up our capacity to deliver life-saving products to patients in a commercial environment. First, breakthrough device designations, which open the door to a potentially faster route toward approval. Second, our therapy gets delivered via a device that needs just a single pivotal trial to win approval. Third, our current device can be used, exactly as it is, across several indications; put differently, there's no need for us to develop bespoke devices for every therapeutic indication we pursue approval in; we think this yields shorter timelines to market plus economies of scale that companies in our sector seldom manage to attain. In summary, we believe we keep generating substantial value for our investors and stakeholders, and we intend to work on closing what we view as a big disconnect between our present market cap and the outlook we hold for the company; with that said, I'll hand it to the operator to begin the Q&A portion. Operator?

Anthony Vendetti

analyst
#7

Thank you. Yeah. My first question is about the NEUTRALIZE-AKI trial. Kevin, I believe you mentioned that 94 patients out of a planned 200 have signed up, and the plan is to do an interim analysis once 100 are in, so enrollment should wrap up near the 90-day mark following that, correct — after patient number 100 joins. Is that right? Since only six more are needed, what's your top guess for which quarter, month, or timeframe that will happen?

Eric Schlorff

executive
#8

Yes. Hi, Anthony. Eric here. Thanks for being with us today. Kevin had to leave, so I'll address your question in a few pieces. First, that's right, we're at 94 patients. We expect to reach 100 probably around the start of April, somewhere in early April. Regarding when we hit 100 patients, yes, it's 90 days. That's the primary endpoint — a 90-day period to assess mortality and/or dialysis dependency. At that time the data will be gathered and then submitted to the IRB or the DSMB for review. We expect that soon after reaching that 90-day point, we'll be in a position to share some of the results and the assessment from the DSMB, or the Data Safety Monitoring Board.

Anthony Vendetti

analyst
#9

Alright. So if I were to map out the timing here, Eric, you'd have roughly early April — let's say the start of April — when those 100 patients get enrolled, and then 90 days on top of that. That takes us, say, to the start of July, plus another couple of weeks to run the analysis before you share it. So you'd be looking at late July or early August for an interim look, or interim analysis.

Eric Schlorff

executive
#10

Yeah. That's pretty much in the right range.

Anthony Vendetti

analyst
#11

That's roughly right. All right, excellent. So I suppose, as you keep rolling out QUELIMMUNE, what do you currently intend to do during 2025 to grow your sales force's capabilities? Perhaps you could just provide a small update on that.

Eric Schlorff

executive
#12

Sure. Tim, would you like to take that question?

Tim Varacek

executive
#13

Okay, Anthony. So, what I'd start with is that, once again, this is a niche market, and I'd say our size fits it well at this point. We've got people out in the field, and on top of that — and this matters — we've got operational support in-house. It genuinely takes the whole group; the commercial side alone isn't what does it. We've got trained nurses who are physically there and will educate these accounts. When an account is set to go live, those nurses will show them how the product gets used. As far as our pipeline goes, there's no lack of new accounts showing interest. With every one of these folks, we're moving through the steps, and honestly each one stands on its own — one account versus the next — when it comes to the steps they take and how quickly they take them. As things stand, I'd say we're pleased with our position. Our pipeline is strong, and heading into 2025, we're simply continuing to work through the IRB process and the customer setup process alongside them.

Anthony Vendetti

analyst
#14

All right. That's useful, Tim. Perhaps — and I realize every customer differs — what insights have you gained from those initial hospital activations? When a customer moves from the pipeline into an activation, what does a standard conversion involve? How much time does that usually require? What does it look like? As I mentioned, what have you taken away from the first hospital?

Tim Varacek

executive
#15

Well, I'd say among the most significant takeaways is the IRB process itself. It genuinely involves a few elements. One is our device, and another is the patient registry, which we've discussed. The device component is actually the easier part of IRB review. The harder part is the registry, since it's in certain respects a structure comparable to — it's essentially a post-surveillance registry. More individuals at the hospital get involved who will eventually assess the patient. They'll collect data generated from that patient's initial profiling. Every one of those factors shapes the entire administrative side of establishing a registry inside a hospital; that demands more thorough scrutiny from an IRB perspective. What was the latter portion of your question, Anthony?

Anthony Vendetti

analyst
#16

Yeah. Thinking about those initial activations, did anything stand out that you'd adjust in how you operate, or handle in a different way?

Tim Varacek

executive
#17

What I'd say is that the lessons we've picked up aren't really things that merit going into on this call. It's more the fine-grained details of simply building a smoother workflow for the customer after we grasp how they behave and the way they get things done, plus adapting both our own approach and the assistance we provide to bring them along. Broadly speaking, at a high level the same process applies across every hospital; it simply separates into distinct pieces once you're dealing with one specific system. Certain ones have far more backing and assets than others. You simply make the most of whatever situation you're given. You collaborate with these folks, and on our side we do whatever it takes to push through that process with them as fast and as efficiently as we can.

Anthony Vendetti

analyst
#18

All right, that's great.

Eric Schlorff

executive
#19

The single thing I'd add to everything you just said, Anthony, is that what we probably learned most importantly was how the IRB process could be separated out. Tim walked through how the HDE approval path works, and that path may bring in items such as the value assessment committee along with purchasing. Then you've got the registry. What we've managed to accomplish recently, I believe, is genuinely beginning to split those apart, since our ties with the FDA have led them to urge us that when we're able to treat patients, we ought to attempt to save a child's life even if the registry isn't standing up and perhaps isn't running at that particular site. Clearly, saving that child is our number one aim. And that, in turn, lets us sell product straight to the hospital.

Anthony Vendetti

analyst
#20

All right, that's great.

David Green

executive
#21

Yes. One thing we've found to be extremely useful is that bringing the intensive care unit physicians and kidney specialists into the process at an early stage also saves a considerable amount of time.

Anthony Vendetti

analyst
#22

All right. That's really useful. I appreciate it. Thanks for the detail. I'll get back in line.

Jackie Cossmon

executive
#23

Thanks, Calvin. I want to thank everyone for being with us on this call covering SeaStar Medical's financial results for the year-end. Should you have any questions, feel free to reach out to us at IR@SeaStarMed.com, or go to our website, where you can find our newest news, along with product, pipeline, and company information. Thanks, and farewell.

Operator

operator
#24

Everyone, that brings this conference call to a close; we appreciate your participation and request that you please hang up your lines.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.